382 related articles for article (PubMed ID: 11085525)
21. Effect of combined therapy with low-dose 5-aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15.
Ishiguro M; Iida S; Uetake H; Morita S; Makino H; Kato K; Takagi Y; Enomoto M; Sugihara K
Ann Surg Oncol; 2007 May; 14(5):1752-62. PubMed ID: 17195906
[TBL] [Abstract][Full Text] [Related]
22. Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents.
Francia G; Green SK; Bocci G; Man S; Emmenegger U; Ebos JM; Weinerman A; Shaked Y; Kerbel RS
Mol Cancer Ther; 2005 Oct; 4(10):1484-94. PubMed ID: 16227397
[TBL] [Abstract][Full Text] [Related]
23. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines.
Kane MF; Loda M; Gaida GM; Lipman J; Mishra R; Goldman H; Jessup JM; Kolodner R
Cancer Res; 1997 Mar; 57(5):808-11. PubMed ID: 9041175
[TBL] [Abstract][Full Text] [Related]
24. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin.
Moreland NJ; Illand M; Kim YT; Paul J; Brown R
Cancer Res; 1999 May; 59(9):2102-6. PubMed ID: 10232595
[TBL] [Abstract][Full Text] [Related]
25. Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance.
de las Alas MM; Aebi S; Fink D; Howell SB; Los G
J Natl Cancer Inst; 1997 Oct; 89(20):1537-41. PubMed ID: 9337351
[TBL] [Abstract][Full Text] [Related]
26. Antisense inhibition of hMLH1 is not sufficient for loss of DNA mismatch repair function in the HCT116+chromosome 3 cell line.
Chauhan DP; Yang Q; Carethers JM; Marra G; Chang CL; Chamberlain SM; Boland CR
Clin Cancer Res; 2000 Oct; 6(10):3827-31. PubMed ID: 11051225
[TBL] [Abstract][Full Text] [Related]
27. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability.
Fleisher AS; Esteller M; Wang S; Tamura G; Suzuki H; Yin J; Zou TT; Abraham JM; Kong D; Smolinski KN; Shi YQ; Rhyu MG; Powell SM; James SP; Wilson KT; Herman JG; Meltzer SJ
Cancer Res; 1999 Mar; 59(5):1090-5. PubMed ID: 10070967
[TBL] [Abstract][Full Text] [Related]
28. Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes.
Durant ST; Morris MM; Illand M; McKay HJ; McCormick C; Hirst GL; Borts RH; Brown R
Curr Biol; 1999 Jan; 9(1):51-4. PubMed ID: 9889125
[TBL] [Abstract][Full Text] [Related]
29. Loss of DNA mismatch repair imparts defective cdc2 signaling and G(2) arrest responses without altering survival after ionizing radiation.
Yan T; Schupp JE; Hwang HS; Wagner MW; Berry SE; Strickfaden S; Veigl ML; Sedwick WD; Boothman DA; Kinsella TJ
Cancer Res; 2001 Nov; 61(22):8290-7. PubMed ID: 11719462
[TBL] [Abstract][Full Text] [Related]
30. Chromosomal autonomy of hMLH1 methylation in colon cancer.
Li H; Myeroff L; Kasturi L; Krumroy L; Schwartz S; Willson JK; Stanbridge E; Casey G; Markowitz S
Oncogene; 2002 Feb; 21(9):1443-9. PubMed ID: 11857087
[TBL] [Abstract][Full Text] [Related]
31. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
Aebi S; Fink D; Gordon R; Kim HK; Zheng H; Fink JL; Howell SB
Clin Cancer Res; 1997 Oct; 3(10):1763-7. PubMed ID: 9815561
[TBL] [Abstract][Full Text] [Related]
32. The mismatch repair protein, hMLH1, mediates 5-substituted halogenated thymidine analogue cytotoxicity, DNA incorporation, and radiosensitization in human colon cancer cells.
Berry SE; Garces C; Hwang HS; Kunugi K; Meyers M; Davis TW; Boothman DA; Kinsella TJ
Cancer Res; 1999 Apr; 59(8):1840-5. PubMed ID: 10213489
[TBL] [Abstract][Full Text] [Related]
33. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on P16, hMLH1 and MGMT genes and DNA methylation in human gastric cancer cells].
Meng CF; Zhu XJ; Dai DQ; Peng G
Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Sep; 12(5):494-7. PubMed ID: 19742343
[TBL] [Abstract][Full Text] [Related]
34. Loss of DNA mismatch repair in acquired resistance to cisplatin.
Aebi S; Kurdi-Haidar B; Gordon R; Cenni B; Zheng H; Fink D; Christen RD; Boland CR; Koi M; Fishel R; Howell SB
Cancer Res; 1996 Jul; 56(13):3087-90. PubMed ID: 8674066
[TBL] [Abstract][Full Text] [Related]
35. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability.
Cunningham JM; Christensen ER; Tester DJ; Kim CY; Roche PC; Burgart LJ; Thibodeau SN
Cancer Res; 1998 Aug; 58(15):3455-60. PubMed ID: 9699680
[TBL] [Abstract][Full Text] [Related]
36. Frequent hypermethylation of the hMLH1 gene promoter in differentiated-type tumors of the stomach with the gastric foveolar phenotype.
Endoh Y; Tamura G; Ajioka Y; Watanabe H; Motoyama T
Am J Pathol; 2000 Sep; 157(3):717-22. PubMed ID: 10980110
[TBL] [Abstract][Full Text] [Related]
37. Cell type-dependent regulation of hMLH1 promoter activity is influenced by the presence of multiple redundant elements.
Warnick CT; Dabbas B; Ilstrup SJ; Ford CD; Strait KA
Mol Cancer Res; 2003 Jun; 1(8):610-8. PubMed ID: 12805408
[TBL] [Abstract][Full Text] [Related]
38. Dual repair modulation reverses Temozolomide resistance in vitro.
Barvaux VA; Ranson M; Brown R; McElhinney RS; McMurry TB; Margison GP
Mol Cancer Ther; 2004 Feb; 3(2):123-7. PubMed ID: 14985452
[TBL] [Abstract][Full Text] [Related]
39. In vitro study of human mutL homolog 1 hypermethylation in inducing drug resistance of esophageal carcinoma.
Cao Y; Chen Y; Huang Y; Liu Z; Li G
Ir J Med Sci; 2017 May; 186(2):257-263. PubMed ID: 26782688
[TBL] [Abstract][Full Text] [Related]
40. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
